Composition and methods to improve stability, dosing, pharmacodynamics and product shelf life of endocannabinoids, phytocannabinoids and synthetic cannabinoids delivered by nasal inhaer
OwnerMichael Willinskyinventor
Life of this patent
Estimating the term…
Abstract
An inhaler-delivery-device-packaged homogenate of solid heterogeneous-lipid particulates carrying lipophilic cannabinoid receptor agonists and/or antagonists, wherein the solid heterogeneous-lipid particles comprises: one (or more) lipid(s) whose melting point(s) is (are) substantially above room temperature; in combination with, one (or more) lipid(s) whose melting point(s) is (are) substantially less than room temperature.
Claims47
An inhaler-delivery-device-packaged homogenate of solid heterogeneous-lipid particulates carrying lipophilic cannabinoid receptor agonists and/or antagonists, said solid heterogeneous-lipid particles comprising:
- a. one (or more) lipid(s) whose melting point(s) is (are) substantially above room temperature;
- in combination with,
- b. one (or more) lipid(s) whose melting point(s) is (are) substantially less than room temperature.
The inhaler-delivery-device-packaged homogenate includes a solid lipid particle homogenate of extracted cannabis-endogenous fats/oils, and further comprises cannabis-endogenous essential oils.
A lipophilic active pharmaceutical ingredient, lipophilic bioactive nonessential nutrient agent or lipophilic essential nutrient, in combination with a carrier comprised of mutually compatible lipids including a first crystalized lipid providing a crystalline structure with a second lipid interstitially disposed within said structure and in close-packing-interfering relation with first lipid crystals thereof, and wherein said first lipid is a solid at room temperature, and said second lipid is a liquid at a temperature of about 21 degrees centigrade.
A method for producing a solid lipid particle pre-homogenate, comprising:
- a. heating a mixture comprising:
- i. a heterogeneous lipid combination including:
- 1. one (or more) lipid(s) whose melting point(s) is (are) substantially above room temperature;
- in combination with,
- 2. one (or more) lipid(s) whose melting point(s) is (are) substantially less than room temperature, and
- ii. one or more of a group selected from lipophilic API, lipophilic bioactive nonessential nutrient, or lipophilic essential nutrient
- b. to above the melting point which is substantially above room temperature sufficient to melt said lipids and reduce said mixtures viscosity;
- c. pre-homogenizing said heated mixture to produce a stable pre-homogenate.
A co-therapeutic combination comprising a subclinical dose of morphine together with a compensatory dose of one or more cannabinoid receptor agonist(s) and or antagonist(s).
A co-therapeutic combination comprising a subclinical does or methadone together with a compensatory dose of one or more cannabinoid receptor agonist(s) and of antagonist(s).
Dependencies are inferred from the claim text.